Good MorningEquity markets wobbled again on Wednesday as hotter than expected inflation data capped gains driven by better-than-expected earnings. Reports from the big banks reveal ongoing improvement in the consumer but that news was overshadowed by inflation fears. The producer price index, a leading indicator of consumer inflation, rose 1.0% from the previous month in an acceleration that drove year-over-year inflation to 7.3%.
The news was compounded by testimony from Fed Chief Jerome Powell who says that inflation has accelerated unexpectedly and that high inflation could linger for months. Even so, the FED Chief says there's no expectation for raising interest rates anytime soon. The next big test for the market will come over the next two days with the release of several important economic data points Featured: 5 dividend stocks worth owning in any market condition (Ad) 
|
Finance | |
While DoorDash (NYSE: DASH) and Airbnb (NASDAQ: ABNB) are among the recent IPOs with the most buzz, they’re actually being trounced in the price-performance department by slightly older IPOs OneMain Holdings (NYSE: OMF), Customers Bancorp (NYSE: CUBI) and InMode (NASDAQ: INMD).
3 Underva... Read the Full Story |
|
From Our Partners | | Renewed tensions involving Iran are putting global oil supplies back in focus - and history shows certain energy stocks respond before the broader market catches on.
A new report identifies three energy stocks emerging from today's supply disruptions. One is already benefiting from the current environment; the other two may not be on your radar yet. | | See which three energy stocks made the list and why they stand out |
|
Markets | |
A friend of mine spent over 10 years in a career that wasn't a great fit. She earned a meager salary, her bosses sighed every time it came time for performance reviews and she didn't advance in her role.
In turn, that affected her earnings, which affected her retirement savings, which affected h... Read the Full Story |
|
Business Services | | Consumer borrowing is one of the key forces that drive the economy, which is why it's so great to see borrowing on credit cards and for auto and student loans surging as our financial system continues to recover from the impacts of the pandemic. The Federal Reserve recently reported that U.S. consum... Read the Full Story |
|
From Our Partners | | Most AI portfolios hold the same handful of chip and software names - and completely ignore the physical layer. One perception-hardware company posted ~49% Q1 revenue growth with four partnership announcements in a single month.
A free report names seven companies building the automation, robotics, and semiconductor-test infrastructure that AI requires to move beyond the data center - including an automation giant that raised full-year guidance after quarterly sales rose ~12%. | | Click here to get your free copy of this report today |
|
Finance | |
A Catch-22 For Wells Fargo
Wells Fargo (NYSE: WFC) is faced with a headwind that has emerged for the entire banking sector. The massive amounts of stimulus pumped into the economy are improving general conditions including consumer health and that is cutting into net interest income. The bank ma... Read the Full Story |
|
Medical | |
The Rebound Is On For Organigram
Organigram (NASDAQ: OGI), and the entire Canadian cannabis market, have been struggling in the wake of the COVID-19 pandemic. It's not that demand has evaporated so much as it is that stores have been closed and people can't get the product. But that's changing. C... Read the Full Story |
|
From Our Partners | | Trader Graham Lindman has built a strategy around a repeating anomaly that appears in the first 60 minutes of every trading day - and it never requires holding positions overnight.
The setup has recently been refined to target up to 100% payouts by holding through the close, with 10 consecutive winning trades logged during one of the most volatile stretches since the Tariff Wars.
A new signal opportunity opens tomorrow. | | See how to join Graham Lindman's next trade before it opens |
|
Finance | |
In the universe of bank stocks, Bank of America (NYSE:BAC) is considered to be one of “the rest.” That is, that many investors view JPMorgan Chase (NYSE:JPM) and Goldman Sachs (NYSE:GS) as “the best.” Anything else pales in comparison.
I’m not going to debate that ... Read the Full Story |
|
Retail/Wholesale | |
Fastenal Reports As-Expected Results
We don't want to imply that Fastenal (NASDAQ: FAST) is in bad shape because it's not. The problem that we are faced with is the same one that we were faced with when the company reported Q1 results. The results are 100% as expected, revenue is supported by pr... Read the Full Story |
|
Consumer Staples | | Consumer staple stocks like PepsiCo (NASDAQ:PEP) can be a great addition to any long-term portfolio, as they are known to hold up well in recessions and provide consistent dividend increases over the years. While they might not be as exciting as some of the cutting-edge tech stocks that have been dr... Read the Full Story |
|
Markets | |
I recently became part of the wave of people leaving their jobs during the "Great Resignation," the mass exodus of workers from their regular nine-to-five jobs. We must all think the grass is greener on the other side, huh? (You and I aren't the only ones. You can find 6 million more gig workers t... Read the Full Story |
|
Retail/Wholesale | |
Clothing retailers including Revolve Group (NYSE: RVLV), Boot Barn (NYSE: BOOT) and Lands’ End (NASDAQ: LE) are trading at new highs as customers spruce up long-neglected wardrobes.
As you might imagine, walk-in traffic is increasing at retail locations, but online ordering took off and bus... Read the Full Story |
|
The Early Bird Stock Of The Day Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. | | View Today's Stock Pick |
|
